Genzyme's Gaucher disease drug hits main goals in 2 Phase III trials

02/18/2013 | Reuters · Fox Business

Eliglustat tartrate, an experimental drug from Sanofi unit Genzyme, met the primary goals of two late-stage trials involving patients with Gaucher disease. Eliglustat was associated with reductions in spleen size and matched Sanofi's Cerezyme in symptom response. The company plans to use the trials in seeking regulatory approval.

View Full Article in:

Reuters · Fox Business

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Medical Director - Cataract
Abbott
Santa Ana, CA
Director, Membership
The Food and Drug Law Institute
Washington, DC
Manager, Compliance
Stryker
Fremont, CA
Associate Director, Legal
Merck Sharp & Dohme
Whitehouse Station, NJ
Vice President, Global Quality Collaboration, Standards & Harmonization
Mylan
Canonsburg, PA